<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Int AIDS Soc</journal-id><journal-id journal-id-type="iso-abbrev">J Int AIDS Soc</journal-id><journal-id journal-id-type="publisher-id">JIAS</journal-id><journal-title-group><journal-title>Journal of the International AIDS Society</journal-title></journal-title-group><issn pub-type="epub">1758-2652</issn><publisher><publisher-name>International AIDS Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25394028</article-id><article-id pub-id-type="pmc">4224775</article-id><article-id pub-id-type="publisher-id">19519</article-id><article-id pub-id-type="doi">10.7448/IAS.17.4.19519</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation &#x02013; Abstract O333</subject></subj-group></article-categories><title-group><article-title>First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Heera</surname><given-names>Jayvant</given-names></name><xref ref-type="aff" rid="AF0001_19519">1</xref></contrib><contrib contrib-type="author"><name><surname>Valluri</surname><given-names>Srinivas</given-names></name><xref ref-type="aff" rid="AF0002_19519">2</xref></contrib><contrib contrib-type="author"><name><surname>Craig</surname><given-names>Charles</given-names></name><xref ref-type="aff" rid="AF0003_19519">3</xref></contrib><contrib contrib-type="author"><name><surname>Fang</surname><given-names>Annie</given-names></name><xref ref-type="aff" rid="AF0004_19519">4</xref></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Neal</given-names></name><xref ref-type="aff" rid="AF0005_19519">5</xref></contrib><contrib contrib-type="author"><name><surname>Meyer</surname><given-names>Ralph Dan</given-names></name><xref ref-type="aff" rid="AF0005_19519">5</xref></contrib><contrib contrib-type="author"><name><surname>Demarest</surname><given-names>James</given-names></name><xref ref-type="aff" rid="AF0006_19519">6</xref></contrib></contrib-group><aff id="AF0001_19519"><label>1</label>Clinical Development, Pfizer Inc, Groton, USA</aff><aff id="AF0002_19519"><label>2</label>Statistics, Pfizer Inc, New York, USA</aff><aff id="AF0003_19519"><label>3</label>Virology, Pfizer Inc, Sandwich, UK</aff><aff id="AF0004_19519"><label>4</label>Clinical Development, Pfizer Inc, New York, USA</aff><aff id="AF0005_19519"><label>5</label>Statistics, Groton, Pfizer Inc, USA</aff><aff id="AF0006_19519"><label>6</label>Virology, ViiV Healthcare, Research Triangle Park, USA</aff><pub-date pub-type="epub"><day>02</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>17</volume><issue>4Suppl 3</issue><elocation-id content-type="doi">19519</elocation-id><permissions><copyright-statement>&#x000a9; 2014 Heera J et al; licensee International AIDS Society</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1_19519"><title>Introduction</title><p>MODERN (A4001095) was the first prospective phase 3 study comparing genotype vs phenotype (Trofile&#x02122;) tropism assessments.</p></sec><sec id="st2_19519"><title>Materials and Methods</title><p>Treatment-na&#x000ef;ve adults with HIV-1 RNA &#x0003e;1000 copies/mL were randomized 1:1 at screening to either genotype or Trofile for tropism assessment. Genotype was determined using the geno2pheno algorithm to assess triplicate HIV-1 gp120 V3 loop sequences (plasma); false-positive rate=10%. R5-virus-infected subjects were then randomized 1:1 to receive Maraviroc (MVC) 150 mg QD or Truvada 200/300 mg QD each with DRV/r 800/100 mg QD. Tropism of screening samples from enrolled subjects was also retrospectively determined using the alternate testing method. Positive predictive values (PPV) were estimated by%R5 subjects with Week 48 HIV-1 RNA &#x0003c; 50 c/mL. PPV for each assay was estimated using the response rate among those randomized to that assay and using model-based response estimates in those with R5 by that assay (at screening or retest).</p></sec><sec id="st3_19519"><title>Results</title><p>The observed response rate was 146/181 (80.7%) for genotype vs 160/215 (74.4%) for Trofile (stratification adjusted difference=6.9%, 95% CI 1.3% to 15%). The model-based estimates of PPV (&#x000b1;SE) were 79.1% (&#x000b1;2.42) and 76.3% (&#x000b1;2.38), respectively (difference = 2.8%, 95% CI &#x02212;2.1% to 7.2%). There was no difference in response rate between assays in the Truvada arm (observed difference=&#x02212; 0.1%, 95% CI &#x02212;6.8% to 6.6%). Most enrolled subjects had R5 results at screening using both assays (285/396 (72%)), and of these subjects, 79.3% (226/285) had HIV-1 RNA &#x0003c;50 c/mL at week 48 (<xref ref-type="table" rid="T0001_19519">Table 1</xref>). The few subjects classified as non-R5 by the alternate assay had similar virologic responses to the concordant R5 group.</p></sec><sec id="st4_19519"><title>Conclusion</title><p>There was a higher MVC response rate and model-based positive predictive value with genotype compared to Trofile, but this difference did not reach statistical significance. The majority of subjects had concordant R5 tropism results. Either phenotype or genotype can effectively predict MVC response.</p></sec></abstract></article-meta></front><body><table-wrap id="T0001_19519" position="float"><label>Table 1</label><caption><p>MVC week 48 response (HIV-1 RNA&#x0003c;50c/mL), <italic>n</italic>/<italic>N</italic> (%)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">MVC week 48 response (HIV-1 RNA&#x0003c;50c/mL), <italic>n</italic>/<italic>N</italic> (%)</th><th align="center" rowspan="1" colspan="1">Trofile R5</th><th align="center" rowspan="1" colspan="1">Trofile non-R5</th><th align="center" rowspan="1" colspan="1">Trofile non-reportable</th><th align="center" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Genotype R5</td><td align="center" rowspan="1" colspan="1">226/285 (79.3)</td><td align="center" rowspan="1" colspan="1">11/14 (78.6)</td><td align="center" rowspan="1" colspan="1">14/19 (73.7)</td><td align="center" rowspan="1" colspan="1">251/318 (78.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Genotype non-R5</td><td align="center" rowspan="1" colspan="1">21/26 (80.8)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">21/26 (80.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Genotype non-reportable</td><td align="center" rowspan="1" colspan="1">34/52 (65.4)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">34/52 (65.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">281/363 (77.4)</td><td align="center" rowspan="1" colspan="1">11/14 (78.6)</td><td align="center" rowspan="1" colspan="1">14/19 (73.7)</td><td align="center" rowspan="1" colspan="1">306/396 (77.3)</td></tr></tbody></table></table-wrap></body></article>